Stem cell breakthrough gets closer to the clinic

By | May 30, 2009

Stem cell breakthrough gets closer to the clinic

The technology for versatile, grow-in-a-dish transplant tissue took a step toward clinical use Thursday when researchers announced they have found a safe way to turn skin cells into stem cells.

Researchers say the method is so promising they hope to apply for approval to begin clinic trials by the middle of next year.

“This is the first safe method of generating patient specific stem cells,” said study author Robert Lanza, the chief scientific officer at Stem Cell & Regenerative Medicine International.

“This technology will soon allow us to expand the range of possible stem cell therapies for the entire human body,” Lanza told AFP.

“This allows us to generate the raw material to solve the problem of rejection (by the immune system) so this is really going to accelerate the field of regenerative medicine.”

The research builds on an award-winning breakthrough in 2007 by Shinya Yamanaka of Kyoto University.

Yamanaka and his team introduced four genes into skin cells, reprogramming them so that they became indistinguishable from embryonic stem cells.

That achievement conjured the distant vision of an almost limitless source of transplant material that would be free of controversy, as it would entail no cells derived from embryos.

But the downside of the technique for creating these so-called induced pluripotent stem cells (iPS) is that the genes are delivered by a “Trojan horse” virus.

Reprogramming cells using a virus modifies their DNA in such a way that they cannot be given to patients without boosting the risk of cancer and genetic mutation.

Other researchers have succeeded in delivering the genes with a method called DNA transfection or using a chemical wash, but these techniques also posed health risks.

via Stem cell breakthrough gets closer to the clinic – Yahoo! News.

One thought on “Stem cell breakthrough gets closer to the clinic

  1. rendev

    Hi
    Induced pluripotent stem (iPS) cells is an alternative methods for studying diseases that are more robust and better simulate how the disease develops in humans. The concerns expressed regarding chimerism may be a bit strong. Technological improvements with traditional ES cell microinjections have resulted in embryos which are 100% derived from the donor, not receipient, cells. Thus the first mice born are true clones of the source ES cells.
    Thanks!

Leave a Reply